Legal basis: art. 56. 1. 2 of Act on Public Offering. & Lt; br / & gt; Sopharma AD (3JR: "BSE-Sofia", SPH: Warsaw Stock Exchange). and a decrease of 11% of export sales. & Lt; br / & gt; In the fifteen months of 2018 sales from sales of 5% compared to the same period in 2017, incl. 5% decrease in export sales. & Lt; br / & gt;
Source: company website, investor relations, current and periodic reports.